CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Achieve Life Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Achieve Life Sciences Inc
22722 29TH DR. SE, SUITE 100
Phone: (425) 686-1500p:425 686-1500 SEATTLE, WA  98021  United States Ticker: ACHVACHV
Business Summary
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Thomas B.King 69 8/21/2024 3/29/2023
President, Director, Chief Medical Officer CindyJacobs 66 3/15/2021 8/21/2008
Chief Executive Officer, Principal Financial Officer, Director RichardStewart 65 8/21/2024 8/1/2017
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OncoGenex Technologies Inc. 1522 217th Place SE, Suite 100 Bothell WA United States

Business Names
Business Name
Achieve Life Science Inc.
Achieve Life Sciences Technologies Inc.
Achieve Pharma UK Limited
4 additional Business Names available in full report.

General Information
Number of Employees: 22 (As of 12/31/2023)
Outstanding Shares: 34,389,946 (As of 9/30/2024)
Shareholders: 18
Stock Exchange: NASD
Federal Tax Id: 954343413
Fax Number: (302) 636-5454
Email Address: info@sonuspharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024